Motus GI to Release First Quarter 2020 Results and Provide a Business Update on May 14th
Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) will announce its Q1 2020 financial results on May 14, 2020, following market close. A conference call will occur at 4:30 p.m. ET to discuss the results and corporate updates. Motus GI specializes in endoscopy solutions aimed at improving clinical outcomes and cost-efficiency in gastrointestinal conditions, featuring the Pure-Vu® System. This device assists in cleaning poorly prepared colons, potentially enhancing colonoscopy quality amidst over 1.5 million annual procedures in the U.S.
Positive
- Motus GI is set to release Q1 2020 financial results, providing insight into company performance.
- The Pure-Vu® System addresses significant unmet needs in bowel preparation, enhancing clinical outcomes.
Negative
- None.
News Market Reaction – MOTS
On the day this news was published, MOTS gained 4.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT LAUDERDALE, Fla., May 04, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.
| Conference Call and Webcast | |
| Date and Time: | May 14th at 4:30 p.m. ET |
| Domestic: | 877-407-0792 |
| International: | 201-689-8263 |
| Passcode: | 13702032 |
| Webcast: | www.motusgi.com or http://public.viavid.com/index.php?id=139155 |
A replay of the webcast will be archived on the Motus GI website, www.motusgi.com, for 90 days following the event.
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
Media Contact:
Gloria Gasaatura
LifeSci Public Relations
(646) 627-8387
ggasaatura@lifescipublicrelations.com
FAQ
When will Motus GI release its Q1 2020 financial results?
What is the Pure-Vu® System?
What time is the Motus GI conference call about Q1 2020 results?
How does the Pure-Vu® System improve colonoscopy procedures?
